Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313781
Status:
COMPLETED
Last Update Posted:
2013-04-11
First Post:
2006-04-10
Brief Title:
Study of CP-751871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer HRPC
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2 Randomized Non-Comparative Two-Arm Open Label Multiple-Center Study Of CP-751871 In Combination With DocetaxelPrednisone In Chemotherapy- Naive Arm A And DocetaxelPrednisone Refractory Arm B Patients With Hormone Insensitive Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2013-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the efficacy of CP-751871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None